Latest posts tagged with #BiotechNews on Bluesky
Pasithea Therapeutics Files Form 13G: Pasithea filed a Form 13G on Apr 8, 2026; SEC 5% threshold and 10-/45-day rules apply. Monitor EDGAR for exact share counts and percent-of-class. 👈 Read full analysis #PasitheaTherapeutics #Form13G #SECRules #BiotechNews #SmallCapStocks
BioNTech Schedules 2026 AGM for May 15: BioNTech filed on Apr 2, 2026 setting its AGM for May 15, 2026; institutional holders will monitor proxy materials and capital-authority proposals in April. 👈 Read full analysis #BioNTech #AGM2026 #HealthcareInvesting #BiotechNews #InvestingInsights
Maia Biotechnology Files Form 8-K on March 31: Maia Biotechnology filed a Form 8-K on Mar 31, 2026 (Investing.com, 13:31:32 GMT); SEC rules require 8-Ks within four business days, making immediate review essential. 👈 Read full analysis #MaiaBiotechnology #Form8K #SEC #BiotechNews #Investing
Telo Genomics Appoints John Farlinger as CEO: Telo Genomics named John Farlinger CEO on Mar 31, 2026 (12:01:53 GMT); market reaction will hinge on the company's forthcoming disclosure of strategy, runway and… 👈 Read full analysis #TeloGenomics #Leadership #BiotechNews #CEOAppointment #MarketStrategy
Imunon GAAP EPS -$6.83 Reported Mar 31, 2026: Imunon reported GAAP EPS of -$6.83 on Mar 31, 2026 (Seeking Alpha). The result raises immediate questions about cash runway and the likelihood of dilutive financing… 👈 Read full analysis #Imunon #GAAPEarnings #BiotechNews #SmallCapStocks #CashRunway
Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.
When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.
#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechNews
Curative Biotechnology Executes 1-for-150 Reverse Split: Curative Biotechnology announced a 1-for-150 reverse split on Mar 23, 2026, cutting shares by ~99.33% and prompting close monitoring of 8-Ks, option… 👈 Read full analysis #CurativeBiotechnology #ReverseSplit #BiotechNews #StockMarket #Finance
China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.
Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.
#Biotech #Pharma #ChinaBiotech #BiotechNews #TechNews
$ATAI surges on Q4 2025 earnings beat, BPL-003 on track for Phase 3 in Q2 2026 for treatment-resistant depression
#ATAIStock #MentalHealthInvesting #BiotechNews
https://a777.lt/VbxyFj
$JADE Rises: Jade Biosciences to Release JADE101 Phase 1 Interim Data in Q2 2026, Phase 2 Trials to Follow
Jade Biosciences to report JADE101 interim data in Q2 2026, starts Phase 2 trials mid-2026
#BiotechNews #JadeBiosciences #InvestInHealthcare
https://a777.lt/XhSo5V
🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.
🔗 Read more: bit.ly/ONCOnews03-M...
#ONCOnews #OncoAlert #OncEd #BiotechNews #PharmaNews #Oncology #Hematology
Gilead’s $7.8B Arcellx buy isn’t just M&A. It’s an “option exercise” on CAR-T: pay up to own the flywheel—manufacturing, label expansion, and the economics of scale.
biotech.industryexaminer.com/gilead-arcel...
#Biotech #CellTherapy #CART #Oncology #M&A #TechNews #BiotechNews #MultipleMyeloma
📰 Streetwise Reports featured Arch Biopartners in a contributed technical analyst opinion discussing the company’s kidney-focused pipeline and recent public disclosures.
🔗 Read the full report here: www.streetwisereports.com/article/2026...
#ArchNews #BiotechNews
CAR-T works. But it’s bespoke: collect cells, engineer, ship back — often 3–6 weeks. Lilly’s up-to-$2.4bn Orna deal bets on in-vivo CAR-T (circular RNA + LNPs) to make an autoimmune “immune reset” scalable. biotech.industryexaminer.com/lilly-orna-i...
#Biotech #CART #EliLilly #TechNews #BiotechNews
New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity.
vist.ly/4qxqu
#longevity #PeptideTherapeutics #DrugDiscovery #BiotechNews #PharmaInnovation #RAndD
🧵 [3/6]
Sec, Tat, or ABC? Understand the export pathways that make or break protein production in bacteria.
🌐 #MolecularBiology #GeneticEngineering #BiotechNews
@alisyngayle.bsky.social @science-george.bsky.social @manjeet786.bsky.social @georgeradics.bsky.social @ustinoff.bsky.social
Investors show appetite for Veradermics’ extended-release oral minoxidil therapy, with Phase 3 trial currently underway.
vist.ly/4qi87
#longevity #BiotechNews #HairLossResearch #SkinHealth #LifeSciences
#GenerateBiomedicines has filed for an #IPO on the #Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly #asthma drug. #lifesciences #biotechnews #respiratoryhealth pharmaphorum.com/news/flagshi...
Preclinical results spotlight a new AI-driven approach to obesity, one tied less to appetite alone and more to long-term metabolic health.
longevity.technology/news/insilic...
#longevity #aiinmedicine #drugdiscovery #obesityresearch #digitalhealth #biotechnews
PMD trial ties functional measures with NAD⁺ and redox biomarkers, offering a pragmatic view of mitochondrial modulation.
longevity.technology/news/mitocho...
#longevity #mitochondria #clinicaltrials #neurodegeneration #biotechnews #translationalmedicine
As shares rebound, investors are weighing whether the biotech’s cancer pipeline could define its next chapter.
longevity.technology/news/biontec...
#longevity #biotechinvesting #mRNA #cancerresearch #biotechnews #futuremedicine
New research suggests diabetes drugs could shield retinal cells and help prevent diabetes-related vision loss.
longevity.technology/news/glp-1-w...
#longevity #GLP1 #metabolichealth #diabetes #visionhealth #retina #healthspan #preventivehealth #weightloss #biotechnews #medicine #agingwell
New fast-track voucher program hits roadblocks, affecting Eli Lilly and Sanofi’s medicines among others.
longevity.technology/news/fda-rev...
#longevity #FDA #biotechnews #pharmanews #weightlossdrug #metabolichealth #GLP1 #drugdevelopment #healthpolicy #clinicaltrials
Early results show weight loss, stronger mobility and preserved muscle in older adults, an uncommon combination in obesity and aging research.
longevity.technology/news/immunis...
#longevity #sarcopenia #musclehealth #clinicaltrials #biotechnews #healthspan #mobility #agingwell
🧠💉 #FTD research update
Investigational COYA 302 showed stable cognition over 6 months in a small FTD trial, alongside rapid & sustained Treg enhancement. FDA has now accepted the IND. Early but promising
🔗 ➡️ www.neurologylive.com/view/investi...
#Neurology #ClinicalTrials #BiotechNews #FDA
Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes.
longevity.technology/news/canada-...
#longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews
With its immune-restoring TRIIM platform in the XPRIZE Healthspan semifinals, the company says the body ‘still remembers how to be young’.
longevity.technology/news/interve...
#longevity #immunology #thymus #immunerejuvenation #inflammaging #healthspan #agingwell #biotechnews
The approval marks a milestone for GLP-1 drugs, expanding access beyond injections as Novo Nordisk prepares for a competitive obesity market.
longevity.technology/news/wegovys...
#longevity #GLP1 #ObesityResearch #MetabolicHealth #BiotechNews #FDAApproval #NovoNordisk
Regenerative medicine firm says new capital gives it breathing room to sharpen its placenta-derived tech aimed at aging and chronic disease.
longevity.technology/news/celular...
#longevity #regenerativemedicine #celltherapy #biotechnews #healthspan #aginginnovation
Thryv Therapeutics is heading to SF for the 44th JPM Conference! We’ll be sharing updates on our SGK1 inhibitor programs and upcoming milestones.
Schedule a meeting: admin@thryvtrx.com
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
